Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of DOXIL/CAELYX in Advanced Ovarian or Breast Cancer
NCT05567601Phase 1Completed
- Sponsor
- Baxter
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegylated liposomal doxorubicin in ovarian cancer and breast cancer (2 arms), sponsored by Baxter. Primary endpoints: Maximum Plasma Concentration (Cmax) of Encapsulated Doxorubicin, Area Under the Curve to Last Measurable Concentration (AUC0-t) of Encapsulated Doxorubicin and 1 more. Started Dec 2023; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT05567601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567601.